argenx SE logo
argenx SE ARGX
$ 836.13 0.31%

Annual report 2024
added 01-24-2026

report update icon

argenx SE Market Cap 2011-2026 | ARGX

As of February 13, 2026 argenx SE has a market cap of $ 25 B


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap argenx SE

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 13.8 B 11.3 B 5.57 B 3.82 B 1.91 B - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
13.8 B 1.91 B 7.27 B

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
1.31 B $ 28.91 4.94 % $ 1.4 B usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
440 M $ 15.03 1.14 % $ 6.13 B irlandaIrlanda
Acer Therapeutics Acer Therapeutics
ACER
12.1 M - 2.71 % $ 14 M usaUSA
Acasti Pharma Acasti Pharma
ACST
40.7 M - 4.01 % $ 150 M canadaCanada
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
291 M $ 4.14 5.61 % $ 353 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Adagene Adagene
ADAG
87.8 M $ 3.18 11.58 % $ 179 M chinaChina
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
4.09 M $ 0.78 -8.44 % $ 4.25 M chinaChina
AlloVir AlloVir
ALVR
49 M - 4.14 % $ 49.1 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
664 K - -11.43 % $ 502 K usaUSA
Biogen Biogen
BIIB
29.4 B $ 198.18 1.37 % $ 29 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
895 M $ 3.47 -1.12 % $ 8.35 B australiaAustralia
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
122 B $ 60.84 1.64 % $ 124 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
22.1 M - - $ 10.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
484 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
BioNTech SE BioNTech SE
BNTX
62.9 B $ 106.92 1.1 % $ 27.2 B germanyGermany
Athira Pharma Athira Pharma
ATHA
16.2 M - - $ 269 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
538 M - -0.23 % $ 916 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
71.4 M - 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
7.37 B $ 217.6 -0.23 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
9.48 M - -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
60.4 M - -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
5.65 B - -6.81 % $ 3.04 B usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
4.13 M - 17.91 % $ 11.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
Brickell Biotech Brickell Biotech
BBI
11.4 M - -5.38 % $ 6.06 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
Athersys Athersys
ATHX
364 M - 3.77 % $ 22.4 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
6.55 B $ 40.32 5.15 % $ 4.16 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
4.39 B $ 53.56 9.46 % $ 4.82 B schweizSchweiz
Avenue Therapeutics Avenue Therapeutics
ATXI
544 K - -52.27 % $ 4.45 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
253 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
424 M $ 1.41 2.32 % $ 360 M britainBritain
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 9.35 0.54 % $ 1.51 B britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
1.83 B $ 14.93 2.02 % $ 4.61 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA